FDA calendar · August 2023 · built from SEC filings

PDUFA dates August 2023: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

1 PDUFA date fell in August 2023: MVASI® (August 29). The FDA calendar also recorded 28 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in August 2023

1 PDUFA target action date in August 2023, soonest first, each linked to the SEC filing or FDA page that disclosed it. Data as of .
PDUFA dateCompanyTickerDrugIndicationSource
August 29, 2023Outlook Therapeutics, Inc.OTLKMVASI® (bevacizumab)SEC 8-K Exhibit 99.1, filed 2026-03-16

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

August 2023: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
August 1, 2023remestemcelMESOComplete Response Letter—CRL issuedFDA Complete Response Letters
Aug 2023Month disclosedMVASI® (bevacizumab)OTLKNDA/BLA submission—CompletedSEC 8-K Exhibit 99.1
Aug 2023Month disclosedEylea®REGNFDA approval—ApprovedSEC 8-K Exhibit 99.1
August 2, 2023Prevymis (letermovir)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
August 4, 2023Zurzuvae (zuranolone)BIIBFDA approvalTo treat postpartum depression Press ReleaseApprovedFDA Novel Drug Approvals
August 9, 2023Talvey (talquetamab-tgvs)JNJFDA approval—ApprovedFDA Novel Drug Approvals
August 11, 2023Botox Cosmetic (onabotulinumtoxina)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
August 11, 2023Akeega (abiraterone acetate; niraparib tosylate)JNJFDA approval—ApprovedopenFDA Drugs@FDA
August 14, 2023Amjevita (adalimumab-atto)AMGNLabel expansion—ApprovedopenFDA Drugs@FDA
August 14, 2023Hepzato (melphalan hydrochloride)DCTHFDA approval—ApprovedopenFDA Drugs@FDA
August 14, 2023KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
August 14, 2023Elrexfio (elranatamab)PFEFDA approval—ApprovedFDA Novel Drug Approvals
August 18, 2023Ingrezza Sprinkle (valbenazine tosylate)NBIXLabel expansion—ApprovedopenFDA Drugs@FDA
August 18, 2023PAVBLU® (aflibercept)REGNFDA approval—ApprovedopenFDA Drugs@FDA
August 18, 2023Veopoz (pozelimab-bbfg)REGNFDA approval—ApprovedFDA Novel Drug Approvals
August 23, 2023Trintellix (vortioxetine hydrobromide)TAKLabel expansion—ApprovedopenFDA Drugs@FDA
August 25, 2023Ilaris (canakinumab)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
August 28, 2023Reblozyl (luspatercept-aamt)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
August 29, 2023MVASI® (bevacizumab)OTLKComplete Response Letter—CRL issuedsec_424b
August 31, 2023Tafinlar (dabrafenib mesylate)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
August 31, 2023Mekinist (trametinib dimethyl sulfoxide)NVSLabel expansion—ApprovedopenFDA Drugs@FDA

August 2023: dated readouts

DateDrugCompanyEventIndicationStatusSource
Aug 2023Month disclosedCABOMETYX® (cabozantinib)EXELTopline readoutmeasurable, extra-pelvic metastatic castration-resistant prostate cancerPositiveSEC Form 10-Q
Aug 2023Month disclosedHummingbirdNVAXTopline readout—Met primary endpointSEC Form 10-Q

August 2023: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Aug 2023Month disclosedzipalertinib (CLN-081)CGEMTrial start—CompletedSEC Form 10-K
Aug 2023Month disclosedneflamapimodCRVOTrial startDLB funded primarilyCompletedSEC Form 10-K
Aug 2023Month disclosedTTI-101TVRDTrial startsufferingCompletedsec_s1
Aug 2023Month disclosedBOS-342PVLATrial start—Completedsec_s1
Aug 2023Month disclosedTRUXIMA® (rituximab)ARTVTrial startclass III or IV LN in August 2023CompletedSEC Form 10-K

Questions

What PDUFA dates are in August 2023?

1 PDUFA date fell in August 2023: MVASI® (August 29). The FDA calendar also recorded 28 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.